![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
October 24, 2024
Posts
More good news from Washington: Last week the House Labor-HHS Subcommittee advanced its FY26 spending bill, increasing both NCI & NIH funding and rejecting the proposed cuts. Thank you for working to prioritize #CancerResearch, patients, & survivors. More:
House committeeās FY26 spending bill increases NCI funding by $48M, NIH by $99M House joins Senate...
The House is on track to join the Senate in rejecting the Trump administrationās budget proposal that would cut ...
bit.ly
"GSK2636771 demonstrated modest single-agent activity among patients with relapsed/refractory cancer having PTEN mutation/deletion with PTEN expression or PTEN protein loss" | @FilipJankuMD, Peter O'Dwyer, Alice Chen, Keith Flaherty et al | @JCOPO_ASCO @theNCI @EAonc
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Read the full article. https://brnw.ch/21wVt20
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P | @FilipJankuMD, Peter O'Dwyer, Alice Chen, Keith Flaherty et al | @JCOPO_ASCO
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Read the full article. https://brnw.ch/21wVt20
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
37
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
